Skip to content
You are now leaving to visit

Akcea and Ionis report positive topline Phase 2 results of AKCEA-APOCIII-L Rx

Favorable safety and tolerability were demonstrated in hypertriglyceridemia patients in the study Primary and key secondary endpoints were met with significant reduction in apoC-III and triglyceride levels More than 90% of patients achieved serum triglycerides ≤ 150 mg/dL at the highest monthly